The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
Narayanan to lead SeQuent through next phase of consolidation and growth
Chicago based virtual reality company reaches AIIMS, assisting in surgical planning and training
Three Indian firms namely Curisin, Immunidex and Telemedicine Indian company are part of the first phase
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
In-house wet testing with live Omicron virus demonstrated that the Antigen test detects the Omicron variant with comparable sensitivity to other variants
The last date to apply for this program is 18th January 2022
The companies were evaluated via a comprehensive, in-depth assessment process that included a sustainability framework of 300 points each for – Purpose, Partnership, Planet and People
This test analyses samples in VTM directly without the need for RNA extraction step
New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha, Gamma and Omicron variants following third dose booster with Vaxzevria
Subscribe To Our Newsletter & Stay Updated
